Of note, data on the prognostic relevance of CDKN1A expression showed that increased expression of CDKN1A were associated with poor prognosis in esophageal, ovarian, prostate cancers, and gliomas (30–36). This evidence concerns the gene CDKN1A and prostate cancer.